- Home
- AOSL vs GHRS Comparison
AOSL vs GHRS Comparison
Compare AOSL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOSL
- GHRS
- Stock Information
- Founded
- AOSL 2000
- GHRS 2018
- Country
- AOSL United States
- GHRS Ireland
- Employees
- AOSL N/A
- GHRS N/A
- Industry
- AOSL Semiconductors
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AOSL Technology
- GHRS Health Care
- Exchange
- AOSL Nasdaq
- GHRS Nasdaq
- Market Cap
- AOSL 616.9M
- GHRS 583.1M
- IPO Year
- AOSL 2010
- GHRS 2021
- Fundamental
- Price
- AOSL $21.41
- GHRS $11.83
- Analyst Decision
- AOSL Buy
- GHRS Strong Buy
- Analyst Count
- AOSL 3
- GHRS 8
- Target Price
- AOSL $32.33
- GHRS $30.63
- AVG Volume (30 Days)
- AOSL 372.5K
- GHRS 149.3K
- Earning Date
- AOSL 05-07-2025
- GHRS 05-08-2025
- Dividend Yield
- AOSL N/A
- GHRS N/A
- EPS Growth
- AOSL N/A
- GHRS N/A
- EPS
- AOSL N/A
- GHRS N/A
- Revenue
- AOSL $680,974,000.00
- GHRS N/A
- Revenue This Year
- AOSL $7.05
- GHRS N/A
- Revenue Next Year
- AOSL $2.54
- GHRS N/A
- P/E Ratio
- AOSL N/A
- GHRS N/A
- Revenue Growth
- AOSL 3.57
- GHRS N/A
- 52 Week Low
- AOSL $15.90
- GHRS $6.00
- 52 Week High
- AOSL $53.29
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AOSL 47.41
- GHRS 59.18
- Support Level
- AOSL $20.27
- GHRS $11.47
- Resistance Level
- AOSL $22.51
- GHRS $13.00
- Average True Range (ATR)
- AOSL 0.90
- GHRS 0.95
- MACD
- AOSL -0.09
- GHRS 0.10
- Stochastic Oscillator
- AOSL 20.91
- GHRS 69.16
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.